MorphoSys RA drug could yield $1B in sales yearly, CEO says

09/23/2012 | Reuters

MorphoSys expects sales of rheumatoid arthritis drug MOR 103 to exceed $1 billion annually if it is approved, CEO Simon Moroney said. The German biotech plans to collaborate with another company to further develop the drug, which proved effective in a Phase I/IIa trial.

View Full Article in:


Published in Brief: